Autres langues Amgen Inc. Sao Paulo

Actions

AMGN34

BRAMGNBDR004

Produits pharmaceutiques

Temps Différé Sao Paulo 17:58:09 01/09/2026			Varia. 5j.	Varia. 1 janv.
79,54 ^BRL	-0,26%		-2,24%	+20,59%

01/09	Le régulateur britannique suspend le Tavneos, un médicament contre les maladies rares, pour les nouveaux patients en raison de données non fiables	RE
01/09	Les laboratoires pharmaceutiques mondiaux ayant officiellement annoncé des accords de prix avec Trump	RE

Autres langues

13:43	Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
01/09	UK regulator suspends rare-disease drug Tavneos for new patients over unreliable data
01/09	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
01/09	UK regulator suspends Amgen's Tavneos for new patients over unreliable data
01/09	UK Regulator Suspends Avacopan Vifor for New Patients
01/09	Donald Trump bereitet neue Vereinbarungen zur Senkung der Medikamentenpreise vor
01/09	Trump prepara nuevos acuerdos para abaratar los medicamentos
31/08	Trump announces new round of drug-pricing deals
31/08	Donald Trump prepares new agreements to reduce drug prices
31/08	Trump administration to announce drug pricing deals
31/08	Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
31/08	Amgen Says Repatha Cuts Death Risk 20% in High-Risk Patients
31/08	AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
28/08	AstraZeneca - Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
27/08	UK Shares Fall as Global Tensions Mount; AstraZeneca Drops
27/08	European Stocks Close Mostly Lower in Thursday Trading as Investors Await Fed Chair Speech
27/08	Global markets live: Apple, Meta, Nvidia, Salesforce, KKR…
27/08	AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients
27/08	AstraZeneca and Amgen announce positive Tezspire trial results in EoE
27/08	Astrazeneca-Medikament Tezspire erreicht Studienziel bei Ösophagitis
27/08	Amgen and AstraZeneca Demonstrate Positive Phase 3 Results For Tezspire In Eosinophilic Esophagitis
27/08	PPHE Hotel Group swings to half-year profit
27/08	AstraZeneca, Amgen's Tezspire Improves Eosinophilic Esophagitis Symptoms in Late-stage Trial
27/08	AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial